


# **Investor Presentation**

Q4FY23 || May 2023

BSE: 543266 | NSE: HERANBA | ISIN: INE694N01015

www.heranba.co.in





This presentation and the accompanying slides (the "Presentation"), which have been prepared by Heranba Industries Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

### **Contents**

O1 Company Overview
SLIDE 04

**Management Team**SLIDE 11

**Quarterly Performance**SLIDE 13

**O4** Financial Performance
SLIDE 18

O5 Strategy for Growth SLIDE 25





Section: 01

**Company Overview** 

Heranba at glance

SLIDE 05

**Intermediaries** 

SLIDE 08

Our journey

SLIDE 06

**Technicals** 

SLIDE 09

Value chain

SLIDE 07

**Formulations** 

SLIDE 10



### Heranba at a Glance



Manufacturing **Facilities** 



65 +Countries Presence



850+ Employees (as of FY23)



60+ Revenue from Institutional customers\*\* (as of FY23)



8500+ Dealers across India



41% Revenue from Exports as % of sales (as of FY23)



~20% Revenue from Top 10 customers (as of FY23)



14.4% ROE# (as of FY23)

## **Our Journey**



#### **CMAC**

Started manufacturing the Intermediate CMAC



#### **FORMULATIONS**

Forward integrated into the manufacturing of Formulations developed from Company's synthetic pyrethroids product portfolio of cypermethrin, alphacypermethrin, deltamethrin, permitherin, lambda cyhalothrin



ISO

Receipt of ISO 9001:2015 certification in respect of production & dispatch of agro Formulations and packing & dispatch of agro based herbicides

#### **EXPORTS**

Exported Technicals and Formulations to more than 65+ countries in the international markets

1996

2002

2005

2006

2014

2019

2020

2021-22



#### **TECHNICALS**

Forward integrated into the manufacturing of Technicals, primarily made from the raw material CMAC and other Intermediates



### **BRANDED** FORMULATIONS

Forward Integrated into Branded Formulations through its own distribution network



#### **TURNOVER**

Achieved Turnover of ₹1000 Crores





### INITIAL PUBLIC OFFERING

Listed on BSE & NSE



Commissioned Unit No. 4 in Vapi

### **Value Chain**




### **Value Chain**


HIL over the years, has scaled up the manufacturing of Intermediates, Technicals and Formulations which form part of the entire value chain of the agrochemicals industry

#### **Manufacturing Process**


- HIL manufactures a wide range of products, and each product has its own unique manufacturing process
- The Company specializes in the manufacturing processes that mainly include chemical reactions of:



 The process of manufacturing can be classified broadly into three stages



## **Intermediaries**





#### **End-use**

Intermediates manufactured are for Company's own captive consumption for manufacturing various
Technicals and Formulations


## **Technicals**

#### Insecticides

- Cypermethrin
- Deltamethrin
- Alpha Cypermethrin
- Acephate
- Lambda Cyhalothrin
- Permethrin
- Profenophos
- Temephos
- Theta Cypermethrin
- Thiamethoxam
- Imidacloprid

#### Herbicides

- Glyphosate
- Metribuzin
- Clodinofop



#### **Fungicides**


- Tricyclazole
- Hexaconazole



### **Formulations**


#### **Insecticides**

- Jayam
- Progress Plus
- Param
- Cypraplus
- Dyken
- Mantra
- Astron
- Signor
- Prompt
- Cypra
- Heraban
- Alpha Shakti
- Henoxa



Silicon Plus

#### **Revenue from Technical and Formulations**





Section: 02

Management




# **Experienced Promoters with Domain Knowledge**

Promoters having a cumulative experience of more than six decades



Mr. Sadashiv K. Shetty
Chairman and Executive Director



- Has an experience of more than three decades in agrochemicals industry
- Mr. Sadashiv K. Shetty is associated with the Company since 1994. He is a stalwart of the agrochemicals industry, with over thirty years of experience in the sector.
- Has galvanized the development of new products and is boosting the capacities & capabilities of the Company
- His skill, Experience & Expertise includes Business Leadership & Operations, Risk Management & Governance, Business Expertise, Strategic Planning, General Management, Functional & Managerial Experience Chemical Industry Expert, Manufacturing, Research & Development, etc.



Mr. Raghuram K. Shetty

Managing Director

- Holds a bachelor's degree in economics, Diploma in Export and Import Management and Commercial Diploma from Department of Education, Bureau of Government Examination
- Has an experience of more than three decades in agrochemicals industry
- Mr. Raghuram K. Shetty is associated with the Company since 1994
- In charge of the overall management and day-to-day affairs of the Company, while also giving shape to the future business strategies
- He is the driving force behind the Business Development, Business Operations, Risk Management & Governance, Finance & Accounting, Functional, Strategic Planning, Procurement, Sales & Marketing, Managerial Operations, International Trade, Export Business Management, Product Development, Plant Setup, Supply Chain, Intellectual Property Rights, etc.



Section: 03

# **Quarterly Performance**

**Management Commentary** 

SLIDE 14

**Quarterly Performance** 

SLIDE 15

**P&L Summary** 

SLIDE 16 & 17



# **FY23 Management Commentary**

Mr. Raghuram K. Shetty, Managing Director of Heranba Industries Limited, commented, "The Company's FY23 revenues stood at ₹13,380 million restricted by unfavourable global economic scenario, inventory build-up in the system and sluggish demand from key export regions. However, we have witnessed decent traction for our formulation products in both domestic and export markets. The EBITDA margins remained muted during FY23 due to lower price realization and higher power & fuel costs. Despite of a challenging year, Heranba's Balance Sheet continues to remain strong with 'Net Debt Free' status coupled with healthy gross cash & cash equivalents balance of INR 1,186 million as on 31st March 2023 fuelling the Company's capex plans.

Heranba's has aptly responded to the recent Gujarat Pollution Control Board (GPCB) closure notice for its Vapi plant. The management is confident to resume the commercial production from the Vapi unit in the coming days and the GPCB's temporary Vapi plant's closure notice has no impact on Heranba's future business operations.


The Company continues to strengthen its product portfolio with new product registrations in both domestic & export markets and leverage its distribution network for delivering growth in the coming years."



## **Quarterly Performance (Standalone)**


# Net Revenue from Operations

(₹ IN MILLION)




# **EBITDA(incl. Other Rev)** and **EBITDA Margin**

(IN ₹ MILLION & %)




#### **PAT and PAT Margin**

(₹ IN MILLION & %)



#### **Business Mix**

(IN %)



# **Profit & Loss Summary (Standalone)**

(Quarterly)

Figures in ₹ Million, except EPS and Margins

PARTICULARS	Q4FY22	Q3FY23	Q4FY23
Revenue from Operations	3,501	2,802	2,589
Other Income	48	9	43
Total Revenue	3,549	2,811	2,632
Total Expenses	2,967	2,627	2,450
Profit Before Tax	583	184	182
Total Tax Expense	157	40	38
Profit After Tax	426	144	143
EPS Basic (₹)	10.64	3.60	3.58
EPS Diluted (₹)	10.64	3.60	3.58
EBITDA (incl. Other income)	673	264	270
EBITDA (incl. Other income) Margin	18.97%	9.41%	10.26%

# **Profit & Loss Summary (Consolidated)**

(Quarterly)

Figures in ₹ Million, except EPS and Margins

PARTICULARS	Q1FY23	Q2FY23	Q3FY23	Q4FY23
Revenue from Operations	3,619	4,207	2,760	2,602
Other Income	44	40	6	31
Total Revenue	3,664	4,247	2,767	2,633
Total Expenses	3,221	3,621	2,603	2,487
Profit Before Tax	440	626	164	146
Total Tax Expense	106	155	37	35
Profit After Tax	334	472	126	112
EPS Basic (₹)	8.36	11.78	3.16	2.79
EPS Diluted (₹)	8.36	11.78	3.16	2.79
FRITRA (in al. Othor in a ama)				
EBITDA (incl. Other income)	505	698	245	236
EBITDA (incl. Other income) Margin	13.78%	16.43%	8.84%	8.95%



Section: 04

# **Financial Performance**

**Key Ratios** 

SLIDE 19

**Financial Summary** 


SLIDE 21



## **Key Financial Metrics (Standalone)**


# **Net Revenue from Operations**

(₹ IN MILLION)




# **EBITDA**(incl. Other Rev) and **EBITDA** Margin

(IN ₹ MILLION & %)




# PAT and PAT Margin

(₹ IN MILLION & %)



# Net Debt/(Cash) and Equity




### **Standalone Business Mix**

Diversified customers base across geographies helps to mitigate risks and benefit from expected growth in agrochemical market


#### **Revenue from Operations**


(IN%)



#### **Revenue from Domestic / Exports**

(% OF SALES)





# **Profit & Loss Summary (Standalone)**

					(\ IIV IVIILLIOIV)	
PARTICULARS	FY19	FY20	FY21	FY22	FY23	
Revenue from Operations	10,044.4	9,513.7	12,186.5	14,503.7	13,243.8	
Other Income	73.9	165.3	70.3	193.5	135.8	
Total Revenue	10,118.4	9,679.1	12,256.8	14,697.2	13,379.6	
Total Expenses	8,897.2	8,390.6	10,173.9	12,144.7	11,938.2	
Profit Before Tax	1,221.2	1,288.4	2,082.9	2,552.5	1,441.4	
Total Tax Expense	467.2	311.9	540.6	661.9	340.3	
Profit After Tax	754.0	976.6	1,542.3	1,890.6	1,101.1	
EPS Basic (₹)	19.31	25.00	39.41	47.25	27.52	
EPS Diluted (₹)	19.31	25.00	39.41	47.25	27.52	
EBITDA (incl. Other Income)	1,388.1	1,458.8	2,283.7	2,791.1	1,746.4	
EBITDA (incl. Other Income) Margin	13.82%	15.33%	18.74%	19.24%	13.01%	

# **Standalone Balance Sheet** (1/2)

					, ,
PARTICULARS	FY19	FY20	FY21	FY22	FY23
Non-Current Assets					
Property, plant and equipment	511.4	954.4	1,334.4	1,934.2	1,859.9
Capital work-in-progress	159.7	377.7	97.0	142.3	420.4
Financial Assets:					
(i) Investments	0.2	37.3	101.0	21.3	9.2
(ii) Loans					531.9
(iii) Other Financial Assets	71.0	84.3	241.7	80.7	58.1
Current tax assets (Net)	1.5		10.2	28.1	70.9
Other non-current assets	344.6	80.7	97.0	72.5	67.8
Total Non-Current Assets (I)	1,088.4	1,534.4	1,881.2	2,279.1	3,018.2
Current Assets					
Inventories	1,138.9	1,455.2	1,659.9	2,557.4	2,971.6
Financial Assets:					
(i) Trade Receivables	2,532.7	2,584.7	3,417.6	4,468.8	3,875.9
(ii) Cash and cash equivalents	209.7	31.9	847.8	1,231.6	1,186.3
(iii) Loans	0.0	9.0			
(iv) Other financial assets	15.4	17.2	20.0	25.5	28.6
Other current assets	619.3	615.4	606.7	516.8	293.4
Total Current Assets (II)	4,516.0	4,713.3	6,551.9	8,800.1	8,355.8
Non-Current Assets held for Sale					219.0
Total Assets (I + II)	5,604.4	6,247.6	8,433.1	11,079.1	11,593.0

## **Standalone Balance Sheet** (2/2)

PARTICULARS	FY19	FY20	FY21	FY22	FY23
Equity and liabilities					
Equity					
Equity share capital	390.6	390.6	400.1	400.1	400.1
Other equity	1,891.2	2,817.9	4,881.2	6,744.4	7,761.0
Total Equity	2,281.8	3,208.5	5,281.3	7,144.5	8,161.1
Liabilities					
Non-Current Liabilities					
Financial Liabilities					
(i) Borrowings					
(ii) Other Financial Liabilities	57.3	61.5	66.4		
Provisions	4.2	6.5	22.4	78.6	89.4
Other Non-current liabilities		2.3	11.7	6.3	35.1
Deferred Tax balances (net)	41.3	16.1			
Total Non-Current Liabilities (I)	102.8	86.3	100.6	84.9	124.5
Current Liabilities					
Financial Liabilities					
(i) Borrowings	498.7	430.8	502.8	895.6	890.1
(ii) Trade payables	2,352.1	2,124.7	1,955.8	2,458.4	1,865.9
(iii) Other Financial Liabilities	121.9	139.3	283.3	295.0	380.2
Current tax Balances (net)	101.7	37.5	88.4	40.1	77.9
Other current liabilities	96.5	163.2	159.7	136.7	77.0
Provisions	49.1	57.4	61.3	23.9	16.3
Total Current Liabilities (II)	3,219.9	2,952.8	3,051.2	3,849.7	3,307.4
Total Liabilities (I + II)	3,322.7	3,039.1	3,151.8	3,934.6	3,431.9
TOTAL EQUITY AND LIABILITIES	5,604.4	6,247.6	8,433.1	11,079.1	11,593.0

## **Standalone Cashflow Statement**

PARTICULARS	FY19	FY20	FY21	FY22	FY23
Cash Flow from Operations	877.02	542.11	603.98	981.1	1,225.0
Cash Flow from Investing Activities	-373.79	-520.39	-407.13	-817.2	-1,000.6
Cash Flow from financing Activities	-411.35	-199.43	619.01	-62.7	-180.8
Net increase/ (decrease) in cash and cash equivalents	91.88	-177.71	815.86	101.1	43.6
Cash and cash equivalents at beginning of the year	117.77	209.65	31.94	847.8	949.0
Cash and cash equivalents at end of the year	209.65	31.94	847.80	949.0	992.6



Section: 05

**Strategy for growth** 

**Competetive Strengths** 

SLIDE 26

**Business Strategy** 

SLIDE 27



# **Competitive Strengths**

**Experienced Promoters and Management Team** 



# **Business Strategy**

Well positioned to exploit opportunities offered by growth in Agrochemicals





#### **Corporate Office**

#### Heranba Industries Ltd.

2nd Floor, A Wing,

Fortune Avirahi,

Jain Derasar Lane,

Borivali (W),

Mumbai – 400 092, India

Tel: 91-22-2898 7912/14,

91-22-2898 2133/44,

91-22-2898 4439,

91-22-5070 5050

Email: compliance@heranba.com

#### **Investor Relations Contacts:**

Hiral Keniya

⊠hiral.keniya@in.ey.com

Vikash Verma

☑ vikash.verma1@in.ey.com

